Press release
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting
- IND filing for CX-801 is anticipated in the second half of 2023 - SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc.
About this update from Cytomx Therapeutics, Inc.
[{"type":"text","content":"- IND filing for CX-801 is anticipated in the second half of 2023 -\nSOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data for CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, Massachusetts. “Interferon alpha is a clinically validated, powerful antitumor agent, but has historically been limited in its clinical use due to toxicity. CX-801, our masked interferon alpha-2b therapeutic candidate, potentially addresses this limitation through a favorable predicted therapeutic index and preferential activity in the tumor micronenvironment,” said Marcia P. Belvin, Ph.D., senior vice president and head of research at CytomX Therapeutics. “At the upcoming SITC Annual Meeting, we will report encouraging preclinical data that support the development of CX-801 based on its single agent activity as well as its enhanced activity when combined with PD-L1 blockade. We plan to explore the clinical potential of CX-801 in tumor types that have traditionally been both responsive and unresponsive to immunotherapy. We look forward to continuing to progress CX-801 towards an investigational new drug application submission in the second half of 2023.” Details for the poster presentation are as follows:Presentation Title: Conditionally Activatable Interferon-alpha 2b Improves Tolerability and Exhibits Preferential Activity in TumorsAbstract Number: 1078Poster HallSession Date and Time: November 10 - 11, 2022, 9:00 am - 9:00 pm ET About CytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments. CytomX’s robust and differentiated pipeline comprises seven therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engaging bispecific antibodies (“TCBs”), and immune modulators such as cytokines and checkpoint inhibitors (“CPIs”). CX-2029 is an investigational conditionally activated antibody-dr...